Tags

Type your tag names separated by a space and hit enter

Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia.
Vaccine. 2005 Apr 15; 23(21):2762-74.V

Abstract

Face-to-face interviews and meetings with more than 160 policymakers and other influential professionals in seven large Asian countries (Bangladesh, China, India, Indonesia, Pakistan, Thailand and Vietnam) were conducted to survey opinions regarding the need for, and potential uses of new-generation vaccines against cholera, typhoid fever and shigellosis. Despite several barriers to their uptake--notably uncertainty of the burden of enteric diseases; preference for water, sanitation and other environmental improvements over vaccination for disease control; and high prices of the current vaccines relative to basic EPI vaccines, and their moderate protection levels--considerable interest was found in the targeted use of Vi typhoid vaccine in most countries, followed by (future) Shigella and oral cholera vaccines. The introduction of these vaccines in Asia could be greatly facilitated by country-specific evidence of disease burden, local or regional vaccine production, field studies demonstrating their safety and efficacy in local populations, evidence of potential economic savings from vaccination, and effective dissemination of research results to all those who make or influence immunization policy.

Authors+Show Affiliations

International Vaccine Institute, San 4-8 Bongcheon-7-dong, Kwanak-gu, Seoul 151-818, South Korea. denise.deroeck@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15780724

Citation

DeRoeck, Denise, et al. "Policymakers' Views Regarding the Introduction of New-generation Vaccines Against Typhoid Fever, Shigellosis and Cholera in Asia." Vaccine, vol. 23, no. 21, 2005, pp. 2762-74.
DeRoeck D, Clemens JD, Nyamete A, et al. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine. 2005;23(21):2762-74.
DeRoeck, D., Clemens, J. D., Nyamete, A., & Mahoney, R. T. (2005). Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine, 23(21), 2762-74.
DeRoeck D, et al. Policymakers' Views Regarding the Introduction of New-generation Vaccines Against Typhoid Fever, Shigellosis and Cholera in Asia. Vaccine. 2005 Apr 15;23(21):2762-74. PubMed PMID: 15780724.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. AU - DeRoeck,Denise, AU - Clemens,John D, AU - Nyamete,Andrew, AU - Mahoney,Richard T, PY - 2004/02/16/received PY - 2004/11/01/revised PY - 2004/11/03/accepted PY - 2005/3/23/pubmed PY - 2005/5/5/medline PY - 2005/3/23/entrez SP - 2762 EP - 74 JF - Vaccine JO - Vaccine VL - 23 IS - 21 N2 - Face-to-face interviews and meetings with more than 160 policymakers and other influential professionals in seven large Asian countries (Bangladesh, China, India, Indonesia, Pakistan, Thailand and Vietnam) were conducted to survey opinions regarding the need for, and potential uses of new-generation vaccines against cholera, typhoid fever and shigellosis. Despite several barriers to their uptake--notably uncertainty of the burden of enteric diseases; preference for water, sanitation and other environmental improvements over vaccination for disease control; and high prices of the current vaccines relative to basic EPI vaccines, and their moderate protection levels--considerable interest was found in the targeted use of Vi typhoid vaccine in most countries, followed by (future) Shigella and oral cholera vaccines. The introduction of these vaccines in Asia could be greatly facilitated by country-specific evidence of disease burden, local or regional vaccine production, field studies demonstrating their safety and efficacy in local populations, evidence of potential economic savings from vaccination, and effective dissemination of research results to all those who make or influence immunization policy. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/15780724/Policymakers'_views_regarding_the_introduction_of_new_generation_vaccines_against_typhoid_fever_shigellosis_and_cholera_in_Asia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(04)00888-6 DB - PRIME DP - Unbound Medicine ER -